Home > Insider Trading > Filing (0001179110-19-011236)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1800	Abbott Laboratories	ABT	Pharmaceutical Preparations (2834)	360698440

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1204554	William Randel Woodgrift	100 Abbott Park Road Abbott Park IL 60064	Senior Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares Without Par Value	Acquisiton	2019-10-23	16,000	$38.40	68,562	No	4	M	Direct
Common Shares Without Par Value	Disposition	2019-10-23	16,000	$80.52	52,562	No	4	S	Direct
Common Shares Without Par Value	Disposition	2019-10-23	5,000	$80.60	47,562	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Option (right to buy)	Disposition	2019-10-23	16,000	$0.00	16,000	$38.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,333	2019-02-19	2026-02-18	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares Without Par Value	2,793	Indirect	Profit Sharing Trust

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.41 to $80.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Balance in the Abbott Laboratories Stock Retirement Trust as of October 23, 2019.
Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.